Drugs / AS15
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy4 trials | ||||||
| Phase 0 | NCT01425749 Background | Jun 2011 → Jul 2013 | melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1 | NCT02364492 Background | Feb 2015 → Oct 2019 | breast cancer | Institut Pasteur | Completed | No outcome recorded |
| Phase 1 | NCT01380145 Background | Sep 2011 → Jul 2014 | plasma cell myeloma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 2 | NCT01437605 Comparator | Oct 2011 → Jul 2018 | melanoma | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AS15 | “AS15 adjuvant” NCT01437605 ↗ |
| Modality | Other / unclassified | “the GSK-proprietary immunostimulant AS15” PMID 32034426 ↗ Feb 2020 |
| Route | Intramuscular | “recMAGE-A3 + AS15 was administered intramuscularly” NCT01380145 ↗ |